Radius Health Inc (RDUS) Given Average Recommendation of “Hold” by Brokerages

Shares of Radius Health Inc (NASDAQ:RDUS) have been given an average recommendation of “Hold” by the thirteen ratings firms that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and six have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $55.25.

Several equities research analysts have commented on RDUS shares. JPMorgan Chase & Co. lowered their price target on shares of Radius Health from $70.00 to $60.00 and set an “overweight” rating on the stock in a report on Monday. Morgan Stanley initiated coverage on shares of Radius Health in a report on Monday, January 29th. They issued an “overweight” rating and a $57.00 price target on the stock. Zacks Investment Research raised shares of Radius Health from a “sell” rating to a “hold” rating in a research note on Monday, January 8th. Cantor Fitzgerald reissued a “buy” rating and set a $58.00 target price on shares of Radius Health in a research note on Friday, November 3rd. Finally, Citigroup initiated coverage on shares of Radius Health in a research note on Wednesday, December 6th. They set a “neutral” rating and a $30.00 target price on the stock.

In other news, major shareholder Growth N. V. Biotech bought 75,000 shares of the stock in a transaction dated Friday, February 9th. The shares were acquired at an average cost of $34.38 per share, with a total value of $2,578,500.00. Following the purchase, the insider now directly owns 5,773,799 shares in the company, valued at approximately $198,503,209.62. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 15.00% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in RDUS. TimesSquare Capital Management LLC raised its position in shares of Radius Health by 184.6% during the 3rd quarter. TimesSquare Capital Management LLC now owns 1,610,365 shares of the biopharmaceutical company’s stock worth $62,080,000 after purchasing an additional 1,044,615 shares during the last quarter. Point72 Asset Management L.P. acquired a new position in shares of Radius Health during the 3rd quarter worth about $17,236,000. Orbimed Advisors LLC raised its position in shares of Radius Health by 59.5% during the 3rd quarter. Orbimed Advisors LLC now owns 1,122,800 shares of the biopharmaceutical company’s stock worth $43,284,000 after purchasing an additional 418,700 shares during the last quarter. BlackRock Inc. raised its position in shares of Radius Health by 10.0% during the 2nd quarter. BlackRock Inc. now owns 2,893,641 shares of the biopharmaceutical company’s stock worth $130,881,000 after purchasing an additional 262,896 shares during the last quarter. Finally, State Street Corp raised its position in shares of Radius Health by 12.9% during the 2nd quarter. State Street Corp now owns 1,867,531 shares of the biopharmaceutical company’s stock worth $84,473,000 after purchasing an additional 213,399 shares during the last quarter.

Shares of Radius Health (NASDAQ:RDUS) opened at $36.42 on Tuesday. Radius Health has a 1-year low of $24.66 and a 1-year high of $49.16. The company has a debt-to-equity ratio of 0.53, a current ratio of 12.87 and a quick ratio of 12.79. The company has a market cap of $1,567.85, a price-to-earnings ratio of -6.71 and a beta of 1.21.

ILLEGAL ACTIVITY NOTICE: This report was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2018/02/20/radius-health-inc-rdus-given-average-recommendation-of-hold-by-brokerages.html.

Radius Health Company Profile

Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

Analyst Recommendations for Radius Health (NASDAQ:RDUS)

Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply